Iterum Therapeutics (NASDAQ:ITRM) versus Synaptogenix (NASDAQ:TAOX) Head-To-Head Survey

Synaptogenix (NASDAQ:TAOX) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Risk and Volatility

Synaptogenix has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.96, suggesting that its share price is 196% more volatile than the S&P 500.

Earnings & Valuation

This table compares Synaptogenix and Iterum Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300,000.00	95.74	-$28.74 million	($3.85)	-1.00
Iterum Therapeutics	$390,000.00	4.10	-$24.77 million	($0.75)	-0.04

Iterum Therapeutics has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Synaptogenix and Iterum Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Iterum Therapeutics	N/A	N/A	-65.54%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Synaptogenix and Iterum Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1	0	0	0	1.00
Iterum Therapeutics	1	2	0	0	1.67

Summary

Iterum Therapeutics beats Synaptogenix on 9 of the 12 factors compared between the two stocks.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.